Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
CORT's Cash-to-Debt is ranked lower than
55% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. CORT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CORT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.72  Med: 538.52 Max: No Debt
Current: No Debt
Equity-to-Asset 0.78
CORT's Equity-to-Asset is ranked higher than
62% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CORT: 0.78 )
Ranked among companies with meaningful Equity-to-Asset only.
CORT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.1  Med: 0.6 Max: 0.89
Current: 0.78
-0.1
0.89
Debt-to-EBITDA 0.13
CORT's Debt-to-EBITDA is ranked higher than
87% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. CORT: 0.13 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CORT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.36  Med: -0.85 Max: 1.43
Current: 0.13
-8.36
1.43
Interest Coverage 44.16
CORT's Interest Coverage is ranked lower than
79% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CORT: 44.16 )
Ranked among companies with meaningful Interest Coverage only.
CORT' s Interest Coverage Range Over the Past 10 Years
Min: 4.99  Med: 5002.5 Max: No Debt
Current: 44.16
Piotroski F-Score: 8
Altman Z-Score: 50.99
Beneish M-Score: -0.83
WACC vs ROIC
9.57%
616.40%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 27.88
CORT's Operating Margin % is ranked higher than
90% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. CORT: 27.88 )
Ranked among companies with meaningful Operating Margin % only.
CORT' s Operating Margin % Range Over the Past 10 Years
Min: -69827.59  Med: -748.74 Max: 27.88
Current: 27.88
-69827.59
27.88
Net Margin % 27.28
CORT's Net Margin % is ranked higher than
90% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. CORT: 27.28 )
Ranked among companies with meaningful Net Margin % only.
CORT' s Net Margin % Range Over the Past 10 Years
Min: -69537.93  Med: -797.39 Max: 27.28
Current: 27.28
-69537.93
27.28
ROE % 64.42
CORT's ROE % is ranked higher than
98% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. CORT: 64.42 )
Ranked among companies with meaningful ROE % only.
CORT' s ROE % Range Over the Past 10 Years
Min: -356.04  Med: -110.44 Max: 64.42
Current: 64.42
-356.04
64.42
ROA % 43.77
CORT's ROA % is ranked higher than
98% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. CORT: 43.77 )
Ranked among companies with meaningful ROA % only.
CORT' s ROA % Range Over the Past 10 Years
Min: -106.94  Med: -73.98 Max: 43.77
Current: 43.77
-106.94
43.77
ROC (Joel Greenblatt) % 5745.95
CORT's ROC (Joel Greenblatt) % is ranked higher than
99% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. CORT: 5745.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CORT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -370585.71  Med: -40045.6 Max: 5745.95
Current: 5745.95
-370585.71
5745.95
3-Year Revenue Growth Rate 88.80
CORT's 3-Year Revenue Growth Rate is ranked higher than
93% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CORT: 88.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CORT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 230.2
Current: 88.8
0
230.2
GuruFocus has detected 3 Warning Signs with Corcept Therapeutics Inc CORT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CORT's 30-Y Financials

Financials (Next Earnings Date: 2018-01-30)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

CORT Guru Trades in Q4 2016

Jim Simons 1,507,500 sh (+169.20%)
Joel Greenblatt 38,010 sh (+81.80%)
First Eagle Investment Sold Out
Paul Tudor Jones Sold Out
» More
Q1 2017

CORT Guru Trades in Q1 2017

Jim Simons 1,858,500 sh (+23.28%)
Joel Greenblatt 11,689 sh (-69.25%)
» More
Q2 2017

CORT Guru Trades in Q2 2017

Louis Moore Bacon 100,000 sh (New)
Joel Greenblatt 59,657 sh (+410.37%)
Jim Simons 2,683,400 sh (+44.39%)
» More
Q3 2017

CORT Guru Trades in Q3 2017

Caxton Associates 10,300 sh (New)
Paul Tudor Jones 34,734 sh (New)
Jim Simons 3,669,755 sh (+36.76%)
Joel Greenblatt 66,450 sh (+11.39%)
Louis Moore Bacon Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CORT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-09-30 Add 11.39%$11.9 - $19.26 $ 18.3924%66,450
Joel Greenblatt 2017-06-30 Add 410.37%0.01%$9.07 - $12.53 $ 18.3969%59,657
Joel Greenblatt 2017-03-31 Reduce -69.25%$7.11 - $11.38 $ 18.39109%11,689
Joel Greenblatt 2016-12-31 Add 81.80%$6.26 - $9.74 $ 18.39135%38,010
First Eagle Investment 2016-12-31 Sold Out $6.26 - $9.74 $ 18.39135%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:XSWX:IDIA, HKSE:01548, SZSE:002653, NAS:INSM, XKRX:006280, SZSE:300294, SZSE:300009, XKRX:084990, NYSE:XON, SZSE:002030, NAS:CBPO, XKRX:086900, NAS:PRTA, NAS:RARE, SZSE:002821, XSWX:GALE, NAS:FOLD, NAS:ARRY, SZSE:300347, NAS:SAGE » details
Traded in other countries:HTD.Germany,
Headquarter Location:USA
Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

Ratios

vs
industry
vs
history
PE Ratio 63.41
CORT's PE Ratio is ranked lower than
84% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. CORT: 63.41 )
Ranked among companies with meaningful PE Ratio only.
CORT' s PE Ratio Range Over the Past 10 Years
Min: 53.3  Med: 107.09 Max: 601
Current: 63.41
53.3
601
PE Ratio without NRI 63.41
CORT's PE Ratio without NRI is ranked lower than
83% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. CORT: 63.41 )
Ranked among companies with meaningful PE Ratio without NRI only.
CORT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 53.3  Med: 107.09 Max: 601
Current: 63.41
53.3
601
Price-to-Owner-Earnings 82.10
CORT's Price-to-Owner-Earnings is ranked lower than
78% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. CORT: 82.10 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CORT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 47.8  Med: 87.77 Max: 667.78
Current: 82.1
47.8
667.78
PB Ratio 24.17
CORT's PB Ratio is ranked lower than
96% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CORT: 24.17 )
Ranked among companies with meaningful PB Ratio only.
CORT' s PB Ratio Range Over the Past 10 Years
Min: 1.82  Med: 15.81 Max: 86.18
Current: 24.17
1.82
86.18
PS Ratio 17.40
CORT's PS Ratio is ranked lower than
63% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. CORT: 17.40 )
Ranked among companies with meaningful PS Ratio only.
CORT' s PS Ratio Range Over the Past 10 Years
Min: 7.23  Med: 117.78 Max: 1990
Current: 17.4
7.23
1990
Price-to-Free-Cash-Flow 56.24
CORT's Price-to-Free-Cash-Flow is ranked lower than
75% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. CORT: 56.24 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CORT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 33.61  Med: 54.46 Max: 195.93
Current: 56.24
33.61
195.93
Price-to-Operating-Cash-Flow 55.56
CORT's Price-to-Operating-Cash-Flow is ranked lower than
80% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. CORT: 55.56 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CORT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 33.21  Med: 54.14 Max: 188.93
Current: 55.56
33.21
188.93
EV-to-EBIT 55.95
CORT's EV-to-EBIT is ranked lower than
89% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. CORT: 55.95 )
Ranked among companies with meaningful EV-to-EBIT only.
CORT' s EV-to-EBIT Range Over the Past 10 Years
Min: -164.1  Med: -5.7 Max: 488.9
Current: 55.95
-164.1
488.9
EV-to-EBITDA 55.84
CORT's EV-to-EBITDA is ranked lower than
89% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. CORT: 55.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
CORT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -171.8  Med: -5.7 Max: 436.4
Current: 55.84
-171.8
436.4
EV-to-Revenue 15.60
CORT's EV-to-Revenue is ranked lower than
59% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. CORT: 15.60 )
Ranked among companies with meaningful EV-to-Revenue only.
CORT' s EV-to-Revenue Range Over the Past 10 Years
Min: 7.1  Med: 76.9 Max: 1373.5
Current: 15.6
7.1
1373.5
Current Ratio 3.85
CORT's Current Ratio is ranked lower than
52% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CORT: 3.85 )
Ranked among companies with meaningful Current Ratio only.
CORT' s Current Ratio Range Over the Past 10 Years
Min: 1.89  Med: 6.84 Max: 37.77
Current: 3.85
1.89
37.77
Quick Ratio 3.70
CORT's Quick Ratio is ranked higher than
50% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. CORT: 3.70 )
Ranked among companies with meaningful Quick Ratio only.
CORT' s Quick Ratio Range Over the Past 10 Years
Min: 1.81  Med: 6.84 Max: 37.77
Current: 3.7
1.81
37.77
Days Inventory 356.88
CORT's Days Inventory is ranked lower than
87% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. CORT: 356.88 )
Ranked among companies with meaningful Days Inventory only.
CORT' s Days Inventory Range Over the Past 10 Years
Min: 355.69  Med: 476.53 Max: 2487.36
Current: 356.88
355.69
2487.36
Days Sales Outstanding 33.40
CORT's Days Sales Outstanding is ranked higher than
77% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. CORT: 33.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
CORT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 33.4  Med: 45.83 Max: 61.48
Current: 33.4
33.4
61.48
Days Payable 768.25
CORT's Days Payable is ranked higher than
89% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. CORT: 768.25 )
Ranked among companies with meaningful Days Payable only.
CORT' s Days Payable Range Over the Past 10 Years
Min: 355.35  Med: 780.49 Max: 15257.8
Current: 768.25
355.35
15257.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.10
CORT's 3-Year Average Share Buyback Ratio is ranked higher than
78% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. CORT: -4.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CORT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -61.6  Med: -20.3 Max: -3.2
Current: -4.1
-61.6
-3.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 40.87
CORT's Price-to-Net-Cash is ranked lower than
91% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. CORT: 40.87 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CORT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.5  Med: 6.63 Max: 376
Current: 40.87
2.5
376
Price-to-Net-Current-Asset-Value 30.15
CORT's Price-to-Net-Current-Asset-Value is ranked lower than
89% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. CORT: 30.15 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CORT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.43  Med: 6.88 Max: 93.33
Current: 30.15
2.43
93.33
Price-to-Tangible-Book 24.17
CORT's Price-to-Tangible-Book is ranked lower than
94% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. CORT: 24.17 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CORT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.31  Med: 6.99 Max: 82.35
Current: 24.17
2.31
82.35
Price-to-Median-PS-Value 0.15
CORT's Price-to-Median-PS-Value is ranked higher than
94% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CORT: 0.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CORT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 0.31 Max: 10.75
Current: 0.15
0.08
10.75
Price-to-Graham-Number 8.24
CORT's Price-to-Graham-Number is ranked lower than
94% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. CORT: 8.24 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CORT' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 7.28  Med: 10.05 Max: 23.74
Current: 8.24
7.28
23.74
Earnings Yield (Greenblatt) % 1.79
CORT's Earnings Yield (Greenblatt) % is ranked higher than
78% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. CORT: 1.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CORT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -311.4  Med: -13.5 Max: 2
Current: 1.79
-311.4
2

More Statistics

Revenue (TTM) (Mil) $129.73
EPS (TTM) $ 0.29
Beta1.20
Short Percentage of Float9.21%
52-Week Range $6.70 - 20.77
Shares Outstanding (Mil)114.12

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}